Human Longevity, Inc. (HLI), a well-known leader in precision health and longevity-centered care, has announced a new partnership with Alamar Biosciences, a company that specializes in precision proteomics. This collaboration is set to introduce new proteomic testing services that will increase scientific understanding of human aging and improve early detection of diseases.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 20 August 2025
As part of this collaboration, HLI will start using two of Alamar’s advanced NULISAseq multiplex panels to improve its diagnostic tools. These panels offer highly sensitive insights into inflammation and neurological health. The NULISAseq Inflammation Panel 250 helps doctors monitor chronic inflammation, which is a key factor in aging and many age-related diseases. The NULISAseq CNS Disease Panel 120 is designed to detect biomarkers linked to brain disorders and neurodegenerative conditions, providing new tools for understanding cognitive health and resilience against aging.
By integrating Alamar’s NULISA proteomics platform with HLI’s experience in multi-omics and its extensive database from over 10,000 clients, the partnership will enable doctors and researchers to monitor biological changes that affect both lifespan and healthspan. This addition increases the precision of HLI’s approach, which already includes genomics, medical imaging, and AI-based analytics.
Health Technology Insights: ARC At Sheba Center and Revealense Launch At-Home AI Neurological Diagnostics
Wei-Wu He, PhD, Executive Chairman of Human Longevity, highlighted the significance of this step, calling proteomics the next big advancement in longevity medicine. He explained that adding detailed protein data to HLI’s existing systems brings them closer to offering preventive healthcare that can predict disease before symptoms appear. He believes that making this cutting-edge science accessible in clinical settings is a major benefit for HLI’s clients.
Yuling Luo, PhD, Founder, Chairman, and CEO of Alamar Biosciences, expressed excitement about the partnership. He is proud to work with a company like HLI, which is a leader in the longevity field. According to Luo, this collaboration is meaningful as it brings advanced science into real-world healthcare, helping people live longer and healthier lives. Later this year, the two proteomic panels will be included in Human Longevity’s Executive Health and 100+ Longevity programs. These services combine advanced diagnostics with personalized care plans and are available to HLI members who are committed to proactive health management. The collaboration reflects a shared vision between HLI and Alamar to advance longevity science through innovative diagnostics, multi-omics data, and clinical AI applications.
Health Technology Insights: ZEISS CIRRUS PathFinder AI Gets CE Mark for OCT Analysis
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
